Hansoh Pharmaceutical
翰森制药
Executive Summary
Hansoh Pharmaceutical is a major Chinese pharma company listed on Hong Kong Stock Exchange, known for its strong oncology pipeline and innovative drug development capabilities. The company has demonstrated active deal-making appetite with international partnerships and maintains a solid regulatory track record. BIOSECURE risk appears manageable as the company is not designated and has clear status, making it a viable partner for US BD teams.
Structure: As a Hong Kong-listed Chinese pharmaceutical company, Hansoh likely operates through a traditional holding company structure rather than a VIE arrangement, which simplifies due diligence processes. The company's mainland China operations are structured through wholly-owned subsidiaries, providing clearer ownership chains for international partnerships.
Ownership & Shareholder Structure
Hansoh Pharmaceutical → AstraZeneca
Hansoh oral GLP-1/GIP dual agonist competes in AZ metabolic franchise.
Clinical Trials(50 total)
4
Phase 3
3
Phase 2
9
Phase 1
2
Phase 1, Phase 2
1
Phase 4
1
Phase 2, Phase 3
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07464327 | HS-20093, Docetaxel | Ph.3 | NOT YET RECRUITING | 450 |
| NCT07283367 | Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin, Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin, Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine | Ph.1, Ph.2 | NOT YET RECRUITING | 502 |
| NCT07115446 | HS-20093, HRS-5041 | Ph.1 | RECRUITING | 63 |
| NCT06963502 | HS-10370, HS-20117, Adebrelimab, Capecitabine, Oxaliplatin, Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan, HS-20093, platinum (cisplatin or carboplatin) | Ph.1 | NOT YET RECRUITING | 762 |
| NCT07181343 | HS-10374 tablets, Drospirenone and Ethinyl Estradiol tablets | Ph.1 | COMPLETED | 18 |
| NCT07040046 | HS-10542, HS-10542 Placebo, HS-10542, HS-10542 Placebo | Ph.1 | RECRUITING | 100 |
| NCT06846710 | HS-20118, HS-20118 placebo | Ph.1 | RECRUITING | 132 |
| NCT06946394 | Pegmolesatide | Ph.4 | NOT YET RECRUITING | 160 |
| NCT07264192 | HS-10518, Placebo | Ph.1 | COMPLETED | 60 |
| NCT06823245 | HS-10241 | Ph.1 | NOT YET RECRUITING | 32 |
| NCT06699576 | HS-20093, Anlotinib, Epirubicin, Adebrelimab | Ph.1 | NOT YET RECRUITING | 448 |
| NCT06052423 | HS-20093 | Ph.2 | WITHDRAWN | 0 |
| NCT06839664 | HS-20094 injection, Placebo injection | Ph.3 | RECRUITING | 610 |
| NCT06526624 | HS-20093 | Ph.3 | NOT YET RECRUITING | 406 |
| NCT07047196 | HS-20116, Medical Chitosan (for intra-articular injection) | Ph.3 | COMPLETED | 192 |
| NCT06393673 | HS-10384 tablet Dose 1, HS-10384 tablet Dose 2, HS-10384-matched placebo tablets | Ph.2 | NOT YET RECRUITING | 195 |
| NCT06417008 | HS-20117, Aumolertinib | Ph.2, Ph.3 | RECRUITING | 1,080 |
| NCT06279286 | HS-10506, Placebo | Ph.1, Ph.2 | UNKNOWN | 312 |
| NCT06336707 | HS-20089, Adebrelimab, Bevacizumab, Cisplatin / carboplatin | Ph.1 | RECRUITING | 1,048 |
| NCT06246565 | HS-10383, HS-10383 Placebo | Ph.2 | NOT YET RECRUITING | 276 |
Showing 20 of 50 trials
Top Publications (by citations)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR, KEYNOTE-604 Investigators.
Polymer-drug conjugate therapeutics: advances, insights and prospects.
Ekladious I, Colson YL, Grinstaff MW.
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC.
Targeting CDK4 and CDK6 in cancer.
Goel S, Bergholz JS, Zhao JJ.
Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro.
Lv LH, Wan YL, Lin Y, Zhang W, Yang M, Li GL, Lin HM, Shang CZ, Chen YJ, Min J.
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ.
<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF.
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M.
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E, RATIONALE-302 Investigators.
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S.
BIOSECURE Risk
Company has clear BIOSECURE status and is not on any designation lists, indicating lower regulatory risk for US partnerships
Key Exposures:
- •Standard China operations exposure
- •Potential future regulatory changes
Mitigation: Company's clear status and Hong Kong listing provide structural mitigation of BIOSECURE risks
BD Intelligence
Therapeutic Areas:
Recent Deals: Limited recent deal activity data available, but company historically active in licensing arrangements
Approach: Direct approach through senior BD channels; company appears receptive to international partnerships given Hong Kong listing and clear regulatory status
Red Flags
- ⚠Limited publicly available management information
- ⚠Need to verify current pipeline status and development timelines
- ⚠Confirm current financial position and deal capacity
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 50
- Publications
- 10
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (50 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (10 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.